glp 1 drug novo nordisk asks FDA to prevent compounders from making GLP-1 knockoffs US FDA accepts Novo Nordisk's

The cardiovascular benefits, demonstrated in the SELECT trial showing reduced heart attack and stroke risk with semaglutide, actually argue in favor of continued use for people with cardiovascular risk factors

Where Hers differentiates is in the additional support offered, including lifestyle coaching, nutrition guidance, and a more responsive customer support infrastructure

The FDA classified BPC-157 as a Category 2 bulk drug substance in 2023, meaning it cannot be compounded by commercial pharmaceutical companies and there is insufficient evidence regarding potential human harm

KLS BPC-157 BPC-157 - , , , ,

S-Acetylglutathione exhibits antiviral efficacy in HSV-1 infected model through inhibition of viral replication

Int J Reprod Biomed 17:1122 Ranjbar KZ, Foroutan T, Eini F (2025) Metformin + sitagliptin combination in PCOS